Core Viewpoint - The company has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatment methods, including new combination therapies [1] Group 1: Partnership Details - The collaboration involves the company's antibody-drug conjugate (ADC) SKB105, which targets integrin β6, and Crescent's bispecific antibody CR-001, which targets programmed cell death-1 (PD-1) and vascular endothelial growth factor (VEGF) [1] - Both candidate drugs are being developed for the treatment of solid tumors, with clinical trials for monotherapy expected to begin in Q1 2026 [1] Group 2: Rights and Financial Terms - The company grants Crescent exclusive rights to research, develop, manufacture, and commercialize SKB105 outside of the U.S., Europe, and Greater China, while Crescent grants the company exclusive rights for CR-001 in Greater China [2] - The financial terms include an upfront payment of $80 million from the company to Crescent, potential milestone payments of up to $1.25 billion, and tiered royalties based on SKB105's net sales [2] - Crescent will pay the company an upfront payment of $20 million, with potential milestone payments of up to $30 million, and tiered royalties based on CR-001's net sales [2]
科伦博泰生物-B(06990.HK)：与Crescent合作共研肿瘤治疗药物